NEW YORK: Michael Rinaldo, managing director of Fleishman-Hillard's global healthcare practice, resigned on Friday.
“It's been 23 years, it's time for a change, and there is a lot happening in the healthcare space,” Rinaldo said. “I'm excited to look into the different possibilities.”
He said he is unsure what Fleishman will do with his position. Rinaldo insisted his departure is not the result of any acrimonious circumstances, and reiterated it was just time to move on.
While Rinaldo said he has talked with several parties, he has not decided on a next move. He added that he is open to working in either the government or private sectors.
In his more than two decades at Fleishman, Rinaldo worked his way up from account supervisor, handling programs for accounts such as AstraZeneca's Prilosec and Nexium, Abbott Laboratories' Synthroid, Smith Kline & French's Tagamet, and Ayerst Laboratories' Inderal.
He also served as the agency's global co-chair for healthcare from 2004 to 2008. Previously, he worked at Creamer Dickson Basford as well as Edelman.
“When I first got to the agency, healthcare was a very small, burgeoning space, with a couple of accounts. Now it's really a world-class, significant player,” Rinaldo said. "Whenever you can be a part of something like that, that's something special to look back on.”